scientific program

Cohorts and Population Studies

CoVICIS builds on extensive network of existing population studies and cohorts co-funded by national and international program

Cohorts and Population Studies

General population studies

Switzerland
Swiss national SARS-CoV-2 genomic and variants surveillance program

Funded by the Swiss Federal Office of Public Health, the aim of this program is to assess the impact and to support surveillance of genetic variants of SARS-CoV-2 circulating in Switzerland, in order to rapidly identify and monitor variants of concern (VOCs) or variants of interest (VOIs).

Click here for more information

South Africa
NGS-SA

Network for Genomic Surveillance in South Africa. NGS-SA is a network of laboratories, scientists and academic institutions who rapidly respond to public health threats. For COVID-19, samples are processed and diagnosed at NHLS and private laboratories. Samples are sequenced in genomic facilities across South Africa.

Click here for more information

Italy
MolETra-S2

Molecular evolution and tracing of SARS-CoV-2 epidemic in Italy. Primary objectives are to study the SARS-CoV-2 genomic epidemiology in Italy, by sequencing a large number of genomes collected in almost all Italian regions; and to identify viral variants and the analysis of their impact on clinical outcome and on public health.

Cohorts and Population Studies

Targeted Population

Targeted Population

Vaccination Cohorts

Ethiopia
SeroVac-Ethiopia

Health Care Workers (HCWs) cohorts in Ethiopia. The AZ ChadOx1 vaccine is used in the study. The primary objective is to characterize SARS CoV-2 strain specific IgG binding and neutralizing antibodies in different health care worker populations (SARS CoV-2 experience versus not experienced, vaccinated versus not vaccinated) at the Jimma Medical Center (JMC) and the St. Paul Hospital in Addis Ababa in association to clinical immune protection and Covid-19 disease.

Switzerland
ZVAC

Zurich Coronavirus Vaccination Cohort: an observational study to assess longer-term immune responses and health status after coronavirus (COVID-19) vaccination (Pfizer/BNT162b2 or mRNA-1273 Moderna) in Zurich, Switzerland. The primary objectives are: 1) Characterize the presence, dynamics and persistence of antibodies produced in response to the different SARS-CoV-2 vaccines over time; 2) Assess the presence and durability of SARS-CoV-2 specific T cell responses, as well as antigen specificity and phenotype in response to the different SARS-CoV-2 vaccines over time.

Click here for more information

Italy
HAnDy

Healthcare workers Antibody Dynamics is a Health Care Workers (HCW) post-vaccination study at the Luigi Sacco University Hospital (LSUH) in Milan. 94% (approximately 600) of the subjects were vaccinated with the Pfizer/BNT162b2 mRNA vaccine. The aim of study is to evaluate immunogenicity, durability of antibody response, breakthrough infections and viral sequencing from NP swabs of ongoing infections.

Targeted Population

Immunocompromised Cohorts

South Africa
Sisonke

Open-label, single-arm phase 3B implementation study to monitor the effectiveness of the single-dose Ad26.COV2.S COVID-19 vaccine among health care workers in South Africa. 
CoVICIS-related activities will be focused on: 1) Breakthrough infections; 2) All COVID-19 hospitalizations; 3) Sub-cohort follow-up studies including HIV positive vaccinees and people with co-morbidities

Click here for more information

Italy
COVAC-ID

Prospective, open-label study on the safety, reactogenicity, immunogenicity and durability of the anti-SARS-CoV-2 vaccine in patients with HIV infection, in cancer patients, dialysis patients and in immunosuppressive therapy with multiple sclerosis, autoimmune rheumatological, renal and gastrointestinal diseases.

France
VACOTRARE

Study of the specific humoral and cellular response during vaccination against SARS-Cov-2 in renal transplant patients. The goal of this study is to evaluate the impact of various immune suppressive regimen, in kidney transplant patients on specific immune responses to SARS-CoV-2 vaccines. The primary objective is to evaluate the frequency of responders after vaccination with SARS-CoV-2 RNA vaccine as assessed by B-cell assays.

Switzerland
ImmunoVax

Towards a vaccine-induced long-term control of SARS-CoV-2 transmission in vulnerable patient populations followed up at the Lausanne University Hospital. The overall aim of this study is to establish a representative, population-based cohort of vulnerable immunocompromised patient populations, i.e. oncologic, haematologic, transplanted, primary immunodeficiency and SID patients, routinely vaccinated with either one of the two approved SARS-CoV-2 RNA vaccines and other vaccines as they are approved for general use in Switzerland and examine the safety, immunogenicity, efficacy and response durability of SARS-CoV-2 vaccines in these patients in a time-dependent fashion.

Targeted Population

Post-COVID-19 Cohorts

Switzerland
ZSAC

Towards a long-term control of SARS-CoV-2 transmission – Identifying the epidemiological, immunological and viral genetic drivers of SARS-CoV-2 transmission and pathogenesis in a representative population-based cohort (Zurich SARS-CoV-2 Cohort). The overall aim of this study is to establish a representative, population-based cohort of individuals infected with SARS-CoV-2 in the Canton of Zurich to characterize clinical outcomes and immunological responses and examine transmission patterns among index cases and their close contacts by leveraging routine contact tracing and study data.

Click here for more information

Switzerland
Post-COV

COVID-19: Immunologic, Virologic and Genetic Determinants of Disease Severity and Long-Term Protective Immunity. SARS-CoV-2 is affecting people in a non-homogenous manner and like other infectious diseases, there are genetic, virologic and immunologic factors that determine the post-infection severity of COVID-19 disease and the long-term protective immunity.
The specific aims of the study are: 1) To identify the clinical sequelae and their degree of severity; 2) To identify the immunological signatures associated with the long-term protective immunity and/or persistence of inflammation;

Italy
PoCHPA

Polyspecialistic ambulatory for the follow up of hospitalized patients with severe COVID 19 and with long COVID syndrome. The primary objectives are: 1) To determine the factors associated with an increased risk of post-COVID syndrome and of long COVID; 2) To evaluate the dynamics of the antibody response to SARS-CoV-2 vaccination in post-COVID and long –COVID patients.

Cohorts and Population Studies

Children Cohorts

Switzerland
Ciao Corona

Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools. The study focuses on the seroprevalence and potential clustering of SARS-CoV-2 infection in children and adolescents attending school, as well as history, symptoms, and risk factors for SARS-CoV-2, health, lifestyle, and quality of life outcomes.

Click here for more information

South Africa
SA COVID KIDS

SARS-CoV-2 Infection in Hospitalised South African Children: A multi-centre collaborative initiative to develop a COVID-19 Paediatric Registry. The overall aim of the SA COVID KIDS study is to create a multi-centre registry to describe the epidemiology, clinical characteristics, and outcome of pediatric SARS-CoV-2 infection in children hospitalised at academic and non-academic hospitals in South Africa.

Italy
SALISARV1

SARS-CoV-2 emerging variants in children: a saliva-based testing surveillance program and clinical spectrum of disease. The objectives of the study are: 1) Surveillance testing program of virus variants by a saliva molecular test in school age children; 2) To investigate the clinical spectrum and severity of SARS-CoV-2 variants in hospitalized children.

  CoVICIS is funded by the European Union’s Horizon Europe Research and Innovation Programme under grant nr 101046041